Baidu
map

JAMA Netw Open:控制血压和血糖可预防房室传导阻滞

2019-05-30 xujing 中国循环杂志

根据JAMA Netw Open发表的一项研究,控制血压和血糖可以有效预防房室传导阻滞。

根据JAMA Netw Open发表的一项研究,控制血压和血糖可以有效预防房室传导阻滞。
 
这项以人群为基础的队列研究纳入6146名社区居民。
 
研究发现,血压升高和血糖水平升高与房室传导阻滞的发生有关。
 
人口归因风险计算表明,血压和血糖水平升高可能与超过一半的房室传导阻滞有关。
 
529名(8.6%)有心脏传导疾病的心电图证据,58名(0.9%)因房室传导阻滞住院。
 
研究人员发现,老年(每增加5年的风险比[HR]为1.34)、男性(HR=2.04)、心肌梗死病史(HR=3.54)、心力衰竭病史(HR=3.33)均与房室传导阻滞有关。
 
两个可控的危险因素收缩压和血糖也与房室传导阻滞独立相关。收缩压每增加10mmHg,房室传导阻滞风险增加22%;空腹血糖每增加20 mg/dl,风险就增加19%。
 
即使在调整了其他主要不良冠状动脉事件后,房室传导阻滞仍与这些危险因素相关。
 
在人群归因风险评估中,研究者估计,如果所有参与者均达到理想血压,47%的房室传导阻滞可能被避免,如果所有参与者都有正常的空腹血糖水平,11%的房室传导阻滞可能被避免。
 
研究者指出,也许是因为起搏器如此成功和迅速地解决了心脏传导阻滞的问题,我们没有把注意力放在这种疾病的预防上,除可防治心肌梗死和心力衰竭外,有效治疗高血压和维持正常血糖可能也是有效的心脏传导阻滞预防策略。
 
原始出处: Kerola T, Eranti A, AroAL, et al. Risk factors associated with atrioventricular block. JAMA Netw Open. 2019, 2(5):e194176. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1649328, encodeId=24c31649328ac, content=<a href='/topic/show?id=e2af54213e3' target=_blank style='color:#2F92EE;'>#房室传导阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54213, encryptionId=e2af54213e3, topicName=房室传导阻滞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dec423798545, createdName=axin017, createdTime=Sun Jun 30 07:34:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988339, encodeId=13da1988339bd, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Wed Apr 15 10:34:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033947, encodeId=68c1203394ebf, content=<a href='/topic/show?id=0edb25862cb' target=_blank style='color:#2F92EE;'>#传导阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25862, encryptionId=0edb25862cb, topicName=传导阻滞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Sun Mar 01 02:34:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734137, encodeId=af991e3413790, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Oct 16 23:34:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727995, encodeId=15c61e2799500, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Aug 14 12:34:00 CST 2019, time=2019-08-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1649328, encodeId=24c31649328ac, content=<a href='/topic/show?id=e2af54213e3' target=_blank style='color:#2F92EE;'>#房室传导阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54213, encryptionId=e2af54213e3, topicName=房室传导阻滞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dec423798545, createdName=axin017, createdTime=Sun Jun 30 07:34:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988339, encodeId=13da1988339bd, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Wed Apr 15 10:34:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033947, encodeId=68c1203394ebf, content=<a href='/topic/show?id=0edb25862cb' target=_blank style='color:#2F92EE;'>#传导阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25862, encryptionId=0edb25862cb, topicName=传导阻滞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Sun Mar 01 02:34:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734137, encodeId=af991e3413790, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Oct 16 23:34:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727995, encodeId=15c61e2799500, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Aug 14 12:34:00 CST 2019, time=2019-08-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1649328, encodeId=24c31649328ac, content=<a href='/topic/show?id=e2af54213e3' target=_blank style='color:#2F92EE;'>#房室传导阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54213, encryptionId=e2af54213e3, topicName=房室传导阻滞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dec423798545, createdName=axin017, createdTime=Sun Jun 30 07:34:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988339, encodeId=13da1988339bd, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Wed Apr 15 10:34:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033947, encodeId=68c1203394ebf, content=<a href='/topic/show?id=0edb25862cb' target=_blank style='color:#2F92EE;'>#传导阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25862, encryptionId=0edb25862cb, topicName=传导阻滞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Sun Mar 01 02:34:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734137, encodeId=af991e3413790, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Oct 16 23:34:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727995, encodeId=15c61e2799500, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Aug 14 12:34:00 CST 2019, time=2019-08-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1649328, encodeId=24c31649328ac, content=<a href='/topic/show?id=e2af54213e3' target=_blank style='color:#2F92EE;'>#房室传导阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54213, encryptionId=e2af54213e3, topicName=房室传导阻滞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dec423798545, createdName=axin017, createdTime=Sun Jun 30 07:34:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988339, encodeId=13da1988339bd, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Wed Apr 15 10:34:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033947, encodeId=68c1203394ebf, content=<a href='/topic/show?id=0edb25862cb' target=_blank style='color:#2F92EE;'>#传导阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25862, encryptionId=0edb25862cb, topicName=传导阻滞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Sun Mar 01 02:34:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734137, encodeId=af991e3413790, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Oct 16 23:34:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727995, encodeId=15c61e2799500, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Aug 14 12:34:00 CST 2019, time=2019-08-14, status=1, ipAttribution=)]
    2019-10-16 canlab
  5. [GetPortalCommentsPageByObjectIdResponse(id=1649328, encodeId=24c31649328ac, content=<a href='/topic/show?id=e2af54213e3' target=_blank style='color:#2F92EE;'>#房室传导阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54213, encryptionId=e2af54213e3, topicName=房室传导阻滞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dec423798545, createdName=axin017, createdTime=Sun Jun 30 07:34:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988339, encodeId=13da1988339bd, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Wed Apr 15 10:34:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033947, encodeId=68c1203394ebf, content=<a href='/topic/show?id=0edb25862cb' target=_blank style='color:#2F92EE;'>#传导阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25862, encryptionId=0edb25862cb, topicName=传导阻滞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Sun Mar 01 02:34:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734137, encodeId=af991e3413790, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Oct 16 23:34:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727995, encodeId=15c61e2799500, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Aug 14 12:34:00 CST 2019, time=2019-08-14, status=1, ipAttribution=)]
    2019-08-14 feather89

相关资讯

吃了降压药,血压为什么还会忽高忽低?

人体的血压反映了心脏对全身血管的供血情况,血压本身就存在一定的昼夜和季节节律性变化,一般冬天比夏天高,白天比晚上高,这是正常的生理反应。但是,对于血压忽高忽低,也就是所谓的血压波动,指的是在一定时间内血压变化的程度。如果频繁发生血压波动或者波动幅度过大,或是波动不符合正常的生理,这都在说明心脏功能有所下降,可能会增加罹患心血管疾病的风险。因此,正确处理血压波动显得尤为重要。那么哪些因素会导致血压忽

BMJ:体重、血压以及吸烟教育对心血管风险的影响

研究认为BMI、收缩压和吸烟行为教育对降低心血管事件风险有重要作用

Neurology:静脉溶栓后远隔微出血的危险因素

在一般人群中,MRI 偶然会发现脑微出血(Cerebral microbleeds,CMB),特别是脑血管病的患者。在急性缺血性卒中患者中,治疗前 MRI 检测到CMB 高负荷与溶栓后脑出血(ICH)有关。

J Hypertens:主动脉缩窄修复的儿童颈动脉内膜中层厚度增加与血压升高有关

由此可见,cIMT与儿童BMI的z评分、男性和CoA修复呈正相关。修复CoA的儿童cIMT增加是因为血压异常升高,大多数患者在临床上都被掩盖了。这些发现值得进一步研究cIMT和其他动脉粥样硬化危险因素,以确定它们对这些高度易感患者的潜在临床影响。

Hypertension:尿钠排泄、血压和心血管疾病以及死亡风险

由此可见,尿钠排泄与心血管风险低的受试者的血压升高相关。无论是摄入高钠还是低钠,都没有使心血管疾病,心力衰竭或死亡风险增加。

Circulation:白藜芦醇不可思议的降压作用,但不是喝红酒能实现的

白藜芦醇是一种多酚类化合物,很多植物中都有它的身影,如蓝莓、石榴、蔓越莓和桑椹等,甚至在花生中也有它的存在。因其具有促进健康和抑制疾病等作用,从保护我们的神经元免受衰老,到潜在的预防癌症,这几年在医学界受到了广泛关注。但因白藜芦醇对人体的有效剂量一直无法满足,因此能实现上述效果还很难。

Baidu
map
Baidu
map
Baidu
map